Partnerships

Eversense, the world’s first and only implantable, long-term CGM is happy to partner with leaders in healthcare who share our commitment to providing unparalleled flexibility, convenience and accuracy to people living with diabetes*

Works with Apple Health badge

Important health information at your fingertips

Learn More

Glooko logo with tagline Better Together

Syncs with diabetes devices, fitness and biometric devices

Learn More

Diabass logo with syringe icon and brand name

One software for all devices

Learn More

Tidepool logo in dotted blue and purple lettering

Turn your diabetes data points into accessible, actionable and meaningful insights.

Learn More

Grifgrips logo featuring blue stylized griffin with text

Strong, gentle, breathable adhesive options for your CGM

Learn More

peelz logo with colorful paint splash design

Pump up your style with medical device stickers.

Learn More

SweetSpot logo with blue hexagon and vertical bar chart icon

Diabetes and CGM Data Management

Learn More

MKT-001584 Rev 6
*Availability of integrated solutions may vary by country and by Eversense product.

Senseonics logo in white
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://global.eversensediabetes.com/safety-information/.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.  For important safety information, see https://global.eversensediabetes.com/safety-information/